Resources

This article explores how Medisafe’s intelligent patient engagement platforms provide unparalleled value to pharmaceutical executives, from driving adherence to surfacing actionable insights, and how these offerings are setting new standards in digitally enabled patient care. Discover the technologies and trends poised to shape pharma’s next competitive advantage.

In this webinar, UCB Pharma and the Les Turner ALS Foundation joined Medisafe discuss the integration of digital tools in innovating rare disease treatment.

This app led to a significant improvement in medication adherence for participants. 93% of patients reported that the app’s medication reminders helped them take their medications on time, a crucial factor in managing chronic conditions like hypertension, diabetes, and heart disease.

Discover the transformative power of RWE and how it can can revolutionize your pharma strategy.

Our recent webinar with Fierce Pharma shows how leading agencies and Medisafe are cracking the code on PCOS and other female-specific conditions.

Medisafe data shows that more than 25% of patients who take a leading asthma medication do so in the morning. Guidelines from the National Asthma Education and Prevention Program (NAEPP) state that this medication should only be taken at night for maximum efficacy.

Can digital health survive economic uncertainty? Explore how pharma’s investment in patient engagement and EHR connectivity is building a recession-proof future for healthcare.

Pharma knows where their pills go, but not what happens next. Explore how digital platforms provide the real-world evidence needed to understand the patient journey beyond the prescription.

Download our latest research showing how supporting patient engagement is not only a growing strategic initiative for pharma companies but is proving to be an impactful value driver.

Results showed that existing patients who joined the Medisafe program saw a 7% increase in adherence pre- vs. post-Medisafe start compared to those not on Medisafe, who showed no statistically significant increase over the same time frame.

Read how Medisafe and Pleio joined forces to help engage patients in their treatment journey through the power of human+digital connection, using a compassionate approach for the digital age to drive better outcomes.

The rising cost of insulin is receiving more attention in the media and medical literature with the American Diabetes Association calling for solutions to insulin affordability. Medisafe data, however, indicate that cost may not be the highest concern for many insulin patients.

Medisafe’s real-world data shows patients treated for depression with a newer antidepressant brand (Brand-SSRI) are experiencing dramatically different perceived results in the first two months of therapy compared to patients on other SSRIs.